natgillin/translations-raw huggingface dataset:
Remicade was studied in a clinical study in 120 patients (age range: 4-17 years old) with active juvenile rheumatoid arthritis despite methotrexate. 
Zdravilo Remicade so proučevali v preskušanju pri 120 bolnikih (razpon starosti od 4 do 17 let), ki so imeli aktivni juvenilni revmatoidni artritis kljub zdravljenju z metotreksatom.
• Other skin problems such as erythema multiforme, lichenoid reactions (itchy reddish-purple skin rash and/or threadlike white-grey lines on mucous membranes), blisters and peeling skin, 
• ostale težave s kožo, kot so multiformni eritem, lihenoidne reakcije (srbeč rdeče-vijoličast kožni izpuščaj in/ali belo-sive nitaste črte na sluznicah), mehurji na koži in luščenje kože, ali turi
In clinical studies 36% of infliximab-treated patients were treated for infections compared with 25% of placebo-treated patients. 
V kliničnih študijah je bilo 36 % bolnikov, zdravljenih z infliksimabom, zdravljenih tudi zaradi okužbe, v primerjavi z 25 % tistih, ki so prejemali placebo.
Remicade contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free'. 
Zdravilo Remicade vsebuje manj kot 1 mmol (23 mg) natrija na odmerek, kar v bistvu pomeni “brez natrija”.
≥ 75% improvement 
≥ 75 % izboljšanje
• Fluid around the lungs (pleural effusion) 
• tekočina okrog pljuč (pleuralni izliv)
Of patients who did not have an infusion reaction during the induction period, 9% experienced an infusion reaction during the maintenance period. 
Med bolniki, ki niso imeli z infuzijo povezane reakcije v času uvajalne faze zdravljenja, pa je imelo to reakcijo v času vzdrževalnega zdravljenja 9 % bolnikov.
In an exploratory clinical study evaluating the use of Remicade in patients with moderate to severe chronic obstructive pulmonary disease (COPD), more malignancies were reported in Remicade-treated patients compared with control patients. 
V poskusnem kliničnem preskušanju za ovrednotenje uporabe zdravila Remicade pri bolnikih z zmerno do hudo kronično obstruktivno pljučno boleznijo (KOPB) so poročali o večjem številu malignomov pri bolnikih, zdravljenih z zdravilom Remicade, kot pri tistih iz kontrolne skupine.
In this situation, Remicade should be re-initiated as a single dose followed by the maintenance dose recommendations described above. 
V tem primeru bolniku najprej ponovno uvedite zdravilo Remicade v enkratnem odmerku, pozneje pa mu spet predpišite vzdrževalni odmerek zdravila v skladu s priporočili, ki so podana zgoraj.
• Signs of an allergic reaction such as swelling of your face, lips, mouth or throat which may cause difficulty in swallowing or breathing, skin rash, hives, swelling of the hands, feet or ankles. 
• znaki alergijske reakcije, na primer otekanje obraza, ustnic, ust ali žrela, ki lahko povzročijo težave pri požiranju ali dihanju, kožni izpuščaj, koprivnica, otekanje dlani, stopal ali gležnjev.
More signs of allergic side effects that may happen up to 12 days after your injection include pain in the muscles, fever, joint or jaw pain, sore throat or headache. 
Drugi znaki z alergijo povezanih neželenih učinkov, ki se lahko pojavijo do 12 dni po prejemu injekcije, so bolečina v mišicah, zvišana telesna temperatura, bolečine v sklepih ali v čeljusti, vnetje žrela ali glavobol;
* P-values represent each infliximab treatment group vs. AZA monotherapy. 
* P vrednosti predstavljajo vsako skupino, zdravljeno z infliksimabom, v primerjavi z monoterapijo z AZA.
EXPRESS evaluated the efficacy of infliximab induction and maintenance therapy in 378 patients with plaque psoriasis. 
V študiji EXPRESS so ovrednotili učinkovitost uvodne in vzdrževalne terapije z infliksimabom pri 378 bolnikih, ki so imeli psoriazo s plaki.
In the second clinical study (IMPACT 2), efficacy and safety of infliximab were studied in 200 patients with active psoriatic arthritis (≥ 5 swollen joints and ≥ 5 tender joints). 
V drugem preskušanju (IMPACT 2) so proučevali učinkovitost in varnost infliksimaba pri 200 bolnikih z aktivnim psoriatičnim artritisom (≥ 5 oteklih sklepov in ≥ 5 bolečih sklepov).
In a developmental toxicity study conducted in mice using an analogous antibody that selectively inhibits the functional activity of mouse TNF, there was no indication of maternal toxicity, embryotoxicity or teratogenicity. 
Študija razvojne toksičnosti, opravljena na miših z uporabo analognega protitelesa, ki selektivno zavira delovanje mišjega TNF, ni pokazala znakov toksičnosti za mater, embriotoksičnosti ali teratogenosti.
Rheumatoid arthritis Crohn's disease Paediatric Crohn's disease 
Revmatoidni artritis Crohnova bolezen Pediatrična Crohnova bolezen
• Contact details of the prescriber 
• Kontaktni podatki zdravnika, ki je predpisal zdravilo.
In most patients, infliximab could be detected in the serum for at least 8 weeks after the recommended single dose of 5 mg/kg for Crohn's disease and the rheumatoid arthritis maintenance dose of 3 mg/kg every 8 weeks. 
Pri večini bolnikov so infliksimab našli v serumu še najmanj 8 tednov po priporočenem enkratnem odmerku za zdravljenje Crohnove bolezni, 5 mg/kg, ali pri vzdrževalnem odmerku za zdravljenje revmatoidnega artritisa, 3 mg/kg na vsakih 8 tednov.
Almost all patients had also received medicines containing azathioprine or 6-mercaptopurine in addition to TNF-blockers. 
Skoraj vsi bolniki so poleg zaviralcev TNF prejeli tudi zdravila, ki vsebujejo azatioprin ali 6-merkaptopurin.
Some of these infections have been fatal; the most frequently reported opportunistic infections with a mortality rate of > 5% include pneumocystosis, candidiasis, listeriosis and aspergillosis. 
Najpogosteje prijavljene oportunistične okužbe s stopnjo smrtnosti > 5 % so bile pnevmocistoza, kandidiaza, listerioza in aspergiloza.
Additional information on special populations 
Dodatne informacije za posebne skupine bolnikov Starejši
All patients were on stable methotrexate doses (median 15 mg/wk) for 6 months prior to enrolment and were to remain on stable doses throughout the study. 
Vsi bolniki so prejemali stalne odmerke metotreksata (mediani odmerek 15 mg/teden) že 6 mesecev pred vključitvijo v študijo in ves čas študije.
Remicade is not likely to affect your ability to drive or use tools or machines. 
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo Remicade verjetno ne vpliva na vašo sposobnost vožnje in upravljanja z orodji ali stroji.
The co-primary endpoints were the proportion of patients in clinical remission (CDAI < 150) at week 30 and time to loss of response through week 54. 
Druga dva primarna končna rezultata sta bila: odstotek bolnikov v klinični remisiji (CDAI < 150) v 30. tednu in čas do izginotja odziva na zdravilo v obdobju do 54. tedna.
In a fertility and general reproductive function study, the number of pregnant mice was reduced following administration of the same analogous antibody. 
V študiji plodnosti in splošne reprodukcijske sposobnosti se je po uporabi istega analognega protitelesa število brejih miši zmanjšalo.
Clinical response at week 8 was similar between those with or without concomitant immunomodulator use at baseline. 
Klinični ozdiv 8. teden je bil podoben med bolniki, ki so na začetku prejemali sočasno imunomodulator, in med tistimi, ki ga niso.
For volumes greater than 250 ml, either use a larger infusion bag (e.g. 500 ml, 1000 ml) or use multiple 250 ml infusion bags to ensure that the concentration of the infusion solution does not exceed 4 mg/ml. 
Da zagotovite, da koncentracija infuzijske raztopine ne preseže 4 mg/ml, za volumne, večje od 250 ml, uporabite večjo infuzijsko vrečko (npr. 500 ml, 1.000 ml) ali uporabite več 250-mililitrskih infuzijskih vrečk.
• Some women being treated for rheumatoid arthritis with Remicade have developed cervical cancer. 
• Pri nekaterih ženskah z revmatoidnim artritisom, ki so se zdravile z zdravilom Remicade, se je pojavil rak materničnega vratu.
Continued therapy should be carefully reconsidered in patients who show no evidence of therapeutic benefit within the first 12 weeks of treatment or after dose adjustment. 
O nadaljevanju terapije pa temeljito premislite pri bolnikih, ki v prvih 12 tednih zdravljenja ali po prilagoditvi odmerka ne kažejo nikakršnih znakov, da jim zdravljenje koristi.
Some of these infections have been fatal; the most frequently reported opportunistic infections with a mortality rate of > 5% include pneumocystosis, candidiasis, listeriosis and aspergillosis (see section 4.4). 
Najpogosteje prijavljene oportunistične okužbe s stopnjo smrtnosti > 5 % so bile pnevmocistoza, kandidiaza, listerioza in aspergiloza (glejte poglavje 4.4).
The safety and efficacy of Remicade in children and adolescents younger than 18 years for the indication of psoriasis have not been established. 
Varnost in učinkovitost zdravila Remicade pri otrocih in mladostnikih, mlajših od 18 let, za indikacijo psoriaza nista bili dokazani.
Among patients in the infliximab 5 mg/kg group who crossed over because of loss of fistula response after week 22, 57% (12/21) responded to re-treatment with infliximab 10 mg/kg every 8 weeks. 
Med bolniki, ki so prejemali 5 mg/kg infliksimaba in zaradi fistul niso odgovorili na zdravljenje po 22 tednih, jih je 57 % (12/21) odgovorilo na ponovno zdravljenje z infliksimabom 10 mg/kg vsakih 8 tednov.
Crohn's disease is an inflammatory disease of the bowel. 
Crohnova bolezen je vnetna bolezen črevesja.
• If you received Remicade while you were pregnant, your baby may also be at higher risk for getting an infection with live vaccines for up to six months after birth. 
• Če ste zdravilo Remicade prejemali v času nosečnosti, lahko tudi pri vašem dojenčku še šest mesecev po rojstvu obstaja večje tveganje za okužbo z živimi cepivi.
Please make sure you also have a list of all other medicines that you are using with you at any visit to a healthcare professional. 
Pri vsakem obisku zdravnika imejte s seboj tudi seznam vseh drugih zdravil, ki jih jemljete.
An association between development of antibodies to infliximab and reduced duration of response has also been observed. 
Opažali so tudi povezavo med nastankom protiteles na infliksimab in zmanjšanim trajanjem odziva na zdravilo.
The other cases represented a variety of different malignancies and included rare malignancies usually associated with immunosuppression. 
Približno v polovici primerov je šlo za limfome, drugi primeri pa so zadevali več različnih malignomov, med drugim tudi redke malignome, ki so običajno povezani z imunosupresijo.
• You have heart failure that is moderate or severe. 
• če imate zmerno ali hudo srčno popuščanje.
The safety and efficacy of Remicade have not been studied in children with Crohn's disease below the age of 6 years. 
Varnosti in učinkovitosti zdravila Remicade pri otrocih s Crohnovo boleznijo, mlajših od 6 let, niso preučevali.
All patients received methotrexate (optimised to 20 mg/wk by week 8) and either placebo, 3 mg/kg or 6 mg/kg infliximab at weeks 0, 2, and 6 and every 8 weeks thereafter. 
Vsi bolniki so prejeli metotreksat (optimirano 20 mg/teden do 8. tedna) in bodisi placebo ali 3 mg/kg ali 6 mg/kg infliksimaba v tednih 0, 2 in 6 in potem na vsakih 8 tednov.
In the Phase IIIb trial in Crohn's disease, SONIC, placebo patients received AZA 2.5 mg/kg/day as active control in addition to placebo infliximab infusions. 
V preskušanju IIIb faze SONIC pri bolnikih s Crohnovo boleznijo, so bolniki iz placebo skupine, poleg placebo infuzij infliksimaba, prejemali kot kontrolno učinkovino AZA v odmerku 2,5 mg/kg na dan.
The overall incidence of infections in C0168T72 was 13/22 (59%) in the every 8 week maintenance treatment group and 14/23 (60.9%) in the every 12 week maintenance treatment group. 
Celotna incidenca okužb v preskušanju C0168T72 je bila 13/22 (59 %) v skupini, ki je dobivala vzdrževalno zdravljenje na 8 tednov, in 14/23 (60,9 %) v skupini, ki je dobivala vzdrževalno zdravljenje na 12 tednov.
• The medicine will be given as an infusion (drip) (over 2 hours) into one of your veins, usually in your arm. After the third treatment, your doctor may decide to give your dose of Remicade over 1 hour. 
• Zdravilo vam bodo dali v obliki infuzije (kapalne) (v času 2 ur) v eno od ven, običajno v roki.
The Health Assessment Questionnaire (HAQ; scale 0-3) was used to measure patients' average change from baseline scores over time, in physical function. 
Vprašalnik za oceno zdravstvenega stanja (HAQ-Health Assessment Questionnaire, lestvica 0 - 3) so uporabljali za merjenje povprečne spremembe vrednosti za funkcijo sklepov s časom, v primerjavi z začetnimi vrednostmi.
If an infusion reaction occurs in association with a shortened infusion, a slower infusion rate may be considered for future infusions if treatment is to be continued. 
Če pri skrajšani infuziji nastopi z njo povezana reakcija in je treba zdravljenje nadaljevati, lahko pri naslednjih infuzijah razmislite o uporabi manjše hitrosti infundiranja.
Following administration of 5 mg/kg Remicade every 8 weeks, the predicted median steady-state infliximab exposure (area under concentration-time curve at steady state, AUCss) in paediatric patients aged 6 years to 17 years was approximately 20% lower than the predicted median steady-state drug exposure in adults. 
Pri uporabi zdravila Remicade 5 mg/kg vsakih 8 tednov je bila napovedana mediana izpostavljenosti infliximabu v stanju dinamičnega ravnovesja (površina pod krivuljo koncentracija-čas v stanju dinamičnega ravnovesja, AUCss) pri pediatričnih bolnikih, starih od 6 let do 17 let, približno 20 % nižja od napovedane madiane izpostavljenosti zdravilu v stanju dinamičnega ravnovesja pri odraslih.
DO NOT SHAKE. 
NE STRESAJTE!
If these medicines do not work well enough, you will be given Remicade to treat your disease. 
Če ta zdravila ne delujejo dovolj dobro, boste prejeli zdravilo Remicade za zdravljenje vaše bolezni.
At week 16, 47 placebo patients with < 10% improvement from baseline in both swollen and tender joint counts were switched to infliximab induction (early escape). 
V 16. tednu je 47 bolnikov na placebu z < 10 % izboljšanjem stanja glede na začetek študije - tako glede števila oteklih kot bolečih sklepov - prešlo na uvedbo infliksimaba (zgodnji umik).
• Treat active Crohn's disease 
• zdravljenje aktivne Crohnove bolezni,
Total peripheral white blood cell counts were minimally affected in infliximab-treated patients, although changes in lymphocytes, monocytes and neutrophils reflected shifts towards normal ranges. 
Na celotno število levkocitov v periferni krvi je zdravilo pri bolnikih, ki so se zdravili z infliksimabom, vplivalo le minimalno, četudi so ugotavljali pomik števila limfocitov, monocitov in nevtrofilcev v smeri proti normalnim vrednostim.
Induction treatment in fistulising active Crohn's disease The efficacy was assessed in a randomised, double-blinded, placebo-controlled study in 94 patients with fistulising Crohn's disease who had fistulae that were of at least 3 months' duration. 
Začetno zdravljenje pri aktivni Crohnovi bolezni s fistulami Učinkovitost zdravila so ocenjevali tudi v randomizirani, dvojno slepi s placebom kontrolirani študiji pri 94 bolnikih s Crohnovo boleznijo s fistulami, ki so trajale najmanj 3 mesece.
Gently swirl the solution by rotating the vial to dissolve the lyophilised powder. 
Z vrtenjem viale rahlo premešajte raztopino, da se bo liofilizirani prašek raztopil.
Patient Reminder Card 
Opozorilna kartica za bolnika
If not used immediately, in use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 °C to 8 °C, unless reconstitution/dilution has been taken place in controlled and validated aseptic conditions, (see section 6.3 above). 
Če je ne uporabite takoj, je za čas in pogoje shranjevanja pred uporabo odgovoren uporabnik in navadno to ne bi smelo presegati 24 ur pri temperaturi med 2 °C in 8 °C, razen če je rekonstitucija/redčenje potekala(o) v nadzorovanih in validiranih aseptičnih pogojih (glejte poglavje 6.3 zgoraj).
Also at week 4, 13/27 (48%) of infliximab-treated patients achieved a clinical remission (CDAI < 150) vs. 1/25 (4%) of placebo-treated patients. 
Prav tako so v 4. tednu pri 13 od 27 bolnikov (48 %), zdravljenih z infliksimabom, dosegli klinično remisijo (CDAI < 150), v primerjavi z 1 od 25 bolnikov (4 %), ki so prejeli placebo.
• You will be monitored while you are given Remicade and also for 1 to 2 hours afterwards. 
• Med prejemanjem zdravila Remicade in še eno do dve uri po tem vas bodo spremljali.
Starting at week 16, placebo patients were switched to infliximab and all patients subsequently received 5 mg/kg infliximab every 8 weeks up to week 46. 
Od 16. tedna naprej so bolniki, ki so prejemali placebo, prešli na jemanje infliksimaba in vsi bolniki so potem prejemali 5 mg/kg infliksimaba na vsakih 8 tednov, do 46. tedna.
Delayed hypersensitivity 
Pozna preobčutljivost
The safety and efficacy of Remicade were assessed in two (ACT 1 and ACT 2) randomised, double-blind, placebo-controlled clinical studies in adult patients with moderately to severely active ulcerative colitis (Mayo score 6 to 12; Endoscopy subscore ≥ 2) with an inadequate response to conventional therapies [oral corticosteroids, aminosalicylates and/or immunomodulators (6-MP, AZA)]. 
Varnost in učinkovitost zdravila Remicade so ocenili v dveh randomiziranih, dvojno slepih in s placebom kontroliranih kliničnih študijah (ACT 1 in ACT 2) pri odraslih bolnikih z zmerno do močno aktivnim ulceroznim kolitisom (ocena Mayo od 6 do 12; delna endoskopska ocena ≥ 2), ki so se nezadostno odzvali na običajno zdravljenje [s peroralnimi kortikosteroidi, aminosalicilati in/ali imunomodulatorji (6-MP, AZA)].
By week 26, twenty weeks after the last induction dose, 30% of patients in the 5 mg/kg group and 13.8% of patients in the 3 mg/kg group were PASI 75 responders. 
dvajset tednov po zadnjem uvodnem odmerku, je 30 % bolnikov iz skupine, ki je prejemala 5 mg/kg, in 13,8 % bolnikov iz skupine, ki je prejemala 3 mg/kg, imelo odziv PASI 75.
Concurrent use of stable doses of oral corticosteroids (≤ 10 mg/day) and/or NSAIDs was permitted, and folate supplementation was given. 
Sočasna uporaba stalnih odmerkov peroralnih kortikosteroidov (≤ 10 mg/dan) in/ali NSAID je bila dovoljena, bolniki pa so prejemali tudi dodatke folata.
In clinical studies delayed hypersensitivity reactions have been uncommon and have occurred after Remicade-free intervals of less than 1 year. 
V kliničnih študijah so bile pozne preobčutljivostne reakcije občasne in so se pojavile po premoru brez prejemanja zdravila Remicade, krajšem od enega leta.
Some patients who developed high titres of antibodies to infliximab had evidence of reduced efficacy. 
Pri nekaterih bolnikih, pri katerih so ugotavljali visok titer protiteles proti infliksimabu, so opažali znake zmanjšane učinkovitosti zdravila.
Remicade is indicated for treatment of severe, active ankylosing spondylitis, in adult patients who have responded inadequately to conventional therapy. 
Remicade je indiciran za zdravljenje hudega aktivnega ankilozirajočega spondilitisa pri odraslih bolnikih, ki so se nezadostno odzvali na konvencionalno terapijo.
Percentage of subjects in clinical response and in sustained clinical response Clinical response at week 8 
Odstotek preiskovancev s kliničnim odzivom in trajnejšim kliničnim odzivom Klinični odziv v 8. tednu
The incidence of serious infections in Remicade-treated patients 65 years and older was greater than in those under 65 years of age. 
Pri bolnikih, zdravljenih z zdravilom Remicade, ki so bili stari 65 let ali več, je bila incidenca resnih okužb večja kot pri bolnikih, ki so bili mlajših od 65 let.
In a developmental toxicity study conducted in mice using an analogous antibody that selectively inhibits the functional activity of mouse TNF, there was no indication of maternal toxicity, embryotoxicity or teratogenicity (see section 5.3). 
Študija razvojne toksičnosti, opravljena na miših z uporabo analognih protiteles, ki selektivno zavirajo delovanje mišjega TNF, ni pokazala nobenih znakov toksičnosti za mater, embriotoksičnosti ali teratogenosti zdravila (glejte poglavje 5.3).
At week 30, the proportion of subjects in clinical remission was higher in the q8 week (59.6%, 31/52) than the q12 week maintenance treatment group (35.3%, 18/51; p = 0.013). 
V 30. tednu je bil delež preiskovancev v klinični remisiji večji pri skupini za vzdrževalno zdravljenje z infuzijami na vsakih 8 tednov (59,6 %, 31/52) kot pri tisti za vzdrževalno zdravljenje z infuzijami na vsakih 12 tednov (35,3 %, 18/51; p = 0,013).
In SPIRIT, the proportion of patients achieving PASI 75 at week 10 was 71.7% in the 3 mg/kg infliximab group, 87.9% in the 5 mg/kg infliximab group, and 5.9% in the placebo group (p < 0.001). 
V študiji SPIRIT je bil delež bolnikov, ki so v 10. tednu dosegli PASI 75, 71,7 % v skupini, ki je prejemala 3 mg/kg infliksimaba, 87,9 % v skupini, ki je prejemala 5 mg/kg infliksimaba, in 5,9 % v skupini, ki je prejemala placebo (p < 0,001).
• Lung or chest infections such as bronchitis or pneumonia 
• okužbe pljuč in prsnega koša, na primer bronhitis ali pljučnica
If active tuberculosis is diagnosed, Remicade therapy must not be initiated (see section 4.3). 
Če postavite diagnozo aktivne tuberkuloze, ne smete uvesti zdravljenja z zdravilom Remicade (glejte poglavje 4.3).
No time-dependency of the Pharmacokinetics was observed. 
Niso opažali časovne odvisnosti farmakokinetike infliksimaba.
• Swelling of the liver (hepatitis) or gall bladder, liver damage 
• otekanje jeter (hepatitis) ali žolčnika, okvara jeter
The efficacy of infliximab was assessed in two multicentre, randomised, double-blind, pivotal clinical studies: ATTRACT and ASPIRE. 
Učinkovitost infliksimaba so ocenjevali v dveh multicentričnih, randomiziranih, dvojno slepih osrednjih preskušanjih: ATTRACT in ASPIRE.
Beginning at week 22, patients who initially responded to treatment and subsequently lost their response were eligible to cross over to active re-treatment every 8 weeks at a dose of infliximab 5 mg/kg higher than the dose to which they were originally randomised. 
Od 22. tedna naprej so bolnikom, ki so se najprej dobro odzvali na zdravljenje, vendar je potem njihov klinični odziv izzvenel, dovolili prehod nazaj na aktivno zdravljenje na vsakih 8 tednov z odmerkom infliksimaba, ki je bil za 5 mg/kg večji od odmerka, za katerega so bili prvotno randomizirani.
• Signs of serious skin problems such as reddish-target-like spots or circular patches often with central blisters on the trunk, large areas of peeling and shedding (exfoliating) skin, ulcers of mouth, throat, nose, genitals and eyes or small pus-filled bumps that can spread over the body. 
• znaki resnih težav s kožo, kot so rdečkaste spremembe z izgledom tarče ali okrogle lise na trupu, pogosto z mehurji v središču, velika področja kože, ki se lušči ali lupi, razjede v ustih, grlu, nosu, na spolovilih in očeh ali majhne gnojne bule, ki se lahko razširijo po celem telesu.
• More children taking Remicade developed infections as compared to adults. 
• V primerjavi z odraslimi so se pri otrocih, ki so uporabljali zdravilo Remicade, pogosteje pojavile okužbe.
Induction treatment in moderately to severely active Crohn's disease The efficacy of a single dose treatment with infliximab was assessed in 108 patients with active Crohn's disease (Crohn's Disease Activity Index (CDAI) ≥ 220 ≤ 400) in a randomised, double-blinded, placebo-controlled, dose-response study. 
Začetno zdravljenje pri zmerno do močno aktivni Crohnovi bolezni Učinkovitost infliksimaba v enkratnem odmerku so ocenjevali pri 108 bolnikih z aktivno Crohnovo boleznijo (indeks aktivnosti Crohnove bolezni [CDAI] ≥ 220 ≤ 400) v randomizirani, dvojno slepi s placebom kontrolirani študiji odziva na različne odmerke zdravila.
2 weeks after your 1 
2 tedna po prvem odmerku tretji odmerek
Periodic screening should continue in women treated with Remicade, including those over 60 years of age. 
Pri ženskah, zdravljenih z zdravilom Remicade, vključno s starejšimi od 60 let, je treba nadaljevati s periodičnimi presejalnimi testi.
• Lung problems (such as oedema) 
• težave s pljuči (na primer edem)